Intellect's new frame of mind

Intellect Neurosciences Inc. is picking up where Mindset BioPharmaceuticals Ltd. left off in 2002 when investor interest in Alzheimer's disease immunotherapies waned. That was right around the time a similar program from Elan Corp. plc and Wyeth ran into safety problems.

Now that Intellect has crossed the Atlantic and AD immunotherapies are back in development, the company plans to begin human testing of both an antibody and a vaccine next year. Intellect also hopes to benefit from increased exposure after a reverse merger into a public shell company earlier this month...